Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study-Reference-Cited by-同舟云学术

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

Published:2015-04 Issue:4 Volume:2 Page:e166-e174
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Cheah Chan Yoon,Belada David,Fanale Michelle A,Janikova Andrea,Czucman Myron S,Flinn Ian W,Kapp Amy V,Ashkenazi Avi,Kelley Sean,Bray Gordon L,Holden Scott,Seymour John F

Publisher

Elsevier BV

Subject

Hematology

Reference37 articles.

1. Current and future management of follicular lymphoma;Salles;Int J Hematol,2012

2. WHO classification of tumours of the haematopoeitic and lymphoid tissues;Swerdlow,2008

3. Rituximab for the treatment of follicular lymphoma;Cheah;Future Oncol,2013

4. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study;Herold;J Clin Oncol,2007

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer;Biomaterials;2025-01

2. Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy;ACS Nano;2024-06-24

3. Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells;Cancer Drug Resistance;2024-04-09

4. Core Fucosylation Mediated by the FucT-8 Enzyme Affects TRAIL-Induced Apoptosis and Sensitivity to Chemotherapy in Human SW480 and SW620 Colorectal Cancer Cells;International Journal of Molecular Sciences;2023-07-25

5. Nanoscale Organization of TRAIL Trimers using DNA Origami to Promote Clustering of Death Receptor and Cancer Cell Apoptosis;Small;2023-03-08